MERILOG SOLOSTAR

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MERILOG SOLOSTAR (MERILOG SOLOSTAR).

How it works

Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action due to slow subcutaneous absorption. It binds to insulin receptors, activating downstream signaling pathways involved in glucose uptake, glycogen synthesis, and lipogenesis.

What the body does with it

Metabolism	Insulin glargine is partially metabolized at the injection site to form active metabolites M1 and M2. The exact enzymes involved are not well characterized, but it is primarily cleared by the liver and kidneys.
Excretion	Approximately 80% of the dose is excreted renally as unchanged drug, with 20% eliminated via bile/feces.
Half-life	Terminal half-life is about 24 hours (range 18–30 hours), allowing once-daily dosing.
Protein binding	99.9% bound to albumin.
Volume of Distribution	0.9 L/kg, indicating distribution primarily into extracellular fluid.
Bioavailability	Subcutaneous: approximately 60–70%.
Onset of Action	Subcutaneous: 1–3 hours for peak plasma concentration; clinical effect (e.g., HbA1c reduction) observed after 1–2 weeks.
Duration of Action	Duration of action is approximately 24 hours, providing full-day coverage with once-daily dosing; clinical effects persist for the treatment interval.

Classification & Brands

Dosing & administration

0.5 mg subcutaneously once a day.

Dosage form	INJECTION
Renal impairment	No dose adjustment required in renal impairment; however, caution is advised in severe impairment (GFR <30 mL/min) due to limited data.
Liver impairment	No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Contraindicated in severe hepatic impairment (Child-Pugh C) due to risk of accumulation.
Pediatric use	Not approved for use in pediatric patients below 18 years of age.
Geriatric use	No specific dose adjustment required; monitor renal function as elderly patients may have decreased renal clearance.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MERILOG SOLOSTAR (MERILOG SOLOSTAR).

Breastfeeding	Insulin lispro is a large polypeptide that is not expected to be excreted into breast milk in clinically relevant amounts due to its molecular weight and oral bioavailability. No M/P ratio is available. It is considered compatible with breastfeeding, but dose adjustments may be needed due to postpartum changes in insulin sensitivity.
Teratogenic Risk	Merilog Solostar (insulin lispro) is a recombinant human insulin analog. Insulin does not cross the placenta in significant amounts, and there is no evidence of teratogenicity in human or animal studies. However, maternal diabetes itself poses risks such as congenital anomalies, macrosomia, and neonatal hypoglycemia. No trimester-specific risks directly attributable to insulin lispro.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to insulin glargine or any of its excipients","During episodes of hypoglycemia"]

Clinical Precautions

Precautions

["Never share a SoloStar pen between patients, even if the needle is changed.","Changes in insulin regimen should be made cautiously and only under medical supervision.","Hypoglycemia is the most common adverse reaction; monitor blood glucose closely.","Severe, life-threatening allergic reactions can occur, including anaphylaxis.","Accidental mix-ups between insulin products have been reported; check label carefully before administration."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

MERILOG SOLOSTAR

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MERILOG SOLOSTAR (MERILOG SOLOSTAR).

How it works

What the body does with it

Metabolism	Insulin glargine is partially metabolized at the injection site to form active metabolites M1 and M2. The exact enzymes involved are not well characterized, but it is primarily cleared by the liver and kidneys.
Excretion	Approximately 80% of the dose is excreted renally as unchanged drug, with 20% eliminated via bile/feces.
Half-life	Terminal half-life is about 24 hours (range 18–30 hours), allowing once-daily dosing.
Protein binding	99.9% bound to albumin.
Volume of Distribution	0.9 L/kg, indicating distribution primarily into extracellular fluid.
Bioavailability	Subcutaneous: approximately 60–70%.
Onset of Action	Subcutaneous: 1–3 hours for peak plasma concentration; clinical effect (e.g., HbA1c reduction) observed after 1–2 weeks.
Duration of Action	Duration of action is approximately 24 hours, providing full-day coverage with once-daily dosing; clinical effects persist for the treatment interval.

Classification & Brands

Dosing & administration

0.5 mg subcutaneously once a day.

Dosage form	INJECTION
Renal impairment	No dose adjustment required in renal impairment; however, caution is advised in severe impairment (GFR <30 mL/min) due to limited data.
Liver impairment	No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Contraindicated in severe hepatic impairment (Child-Pugh C) due to risk of accumulation.
Pediatric use	Not approved for use in pediatric patients below 18 years of age.
Geriatric use	No specific dose adjustment required; monitor renal function as elderly patients may have decreased renal clearance.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MERILOG SOLOSTAR (MERILOG SOLOSTAR).

Breastfeeding	Insulin lispro is a large polypeptide that is not expected to be excreted into breast milk in clinically relevant amounts due to its molecular weight and oral bioavailability. No M/P ratio is available. It is considered compatible with breastfeeding, but dose adjustments may be needed due to postpartum changes in insulin sensitivity.
Teratogenic Risk	Merilog Solostar (insulin lispro) is a recombinant human insulin analog. Insulin does not cross the placenta in significant amounts, and there is no evidence of teratogenicity in human or animal studies. However, maternal diabetes itself poses risks such as congenital anomalies, macrosomia, and neonatal hypoglycemia. No trimester-specific risks directly attributable to insulin lispro.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to insulin glargine or any of its excipients","During episodes of hypoglycemia"]